Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday, ValuEngine reports.

JAZZ has been the subject of a number of other research reports. TheStreet raised Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Barclays lifted their price objective on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Piper Jaffray Companies cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $205.00 to $142.00 in a research note on Wednesday, August 21st. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, July 3rd. Finally, Oppenheimer set a $176.00 price target on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, July 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $169.86.

JAZZ stock traded up $1.87 during trading on Tuesday, hitting $127.16. 1,281,916 shares of the company traded hands, compared to its average volume of 564,411. The firm has a market capitalization of $7.16 billion, a PE ratio of 10.39, a P/E/G ratio of 1.04 and a beta of 1.10. Jazz Pharmaceuticals has a 1 year low of $113.52 and a 1 year high of $169.82. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. The company has a 50-day moving average of $133.17 and a 200-day moving average of $134.77.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.49. The company had revenue of $534.13 million during the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $3.49 EPS. Sell-side analysts expect that Jazz Pharmaceuticals will post 13.44 EPS for the current year.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 4,371 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $135.65, for a total transaction of $98,481.90. Following the transaction, the director now owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of JAZZ. Machina Capital S.A.S. bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth approximately $29,000. Signaturefd LLC increased its position in shares of Jazz Pharmaceuticals by 56.3% during the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 72 shares in the last quarter. Captrust Financial Advisors raised its holdings in Jazz Pharmaceuticals by 120.0% in the 2nd quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 120 shares during the last quarter. Stonebridge Capital Advisors LLC bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Finally, Clear Perspective Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $81,000. Institutional investors own 87.83% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Why do companies pay special dividends?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.